We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Proteros and Hutchison MediPharma enter into Long-Term Research Collaboration Agreement

Read time: Less than a minute

Under the agreement Proteros initially will provide high quality crystallography services on certain projects to support HMP’s drug discovery projects. HMP is focused on the areas of oncology and autoimmune diseases.  Proteros will support HMP’s discovery research with Protein-Ligand-structure analysis throughout 2011 and beyond with selected compounds from HMP.  This collaboration will significantly accelerate HMP’s drug discovery process, particularly in medicinal chemistry.

Cony D’Cruz, Chief Business Officer and President Proteros US, Inc. stated, “We are very pleased to be selected by Hutchison MediPharma to work with it on its multitude of exciting targets and we believe that our in-depth structural biology expertise is particularly suited to accelerate its efforts in its target areas.”

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.